Sickle Cell Innovators Required: Emmaus' Pending Approval Highlights Rare Disease Void

 
• By Lucie Ellis-Taitt

FDA approval is likely for Emmaus' sickle cell drug L-glutamine this summer, representing the first new product for the disease since 1998 – a decision FDA advisory committee panelists hope will spur more innovation.

Sickel cell anemia
First sickle cell drug in almost two decades is set for US approval this summer • Source: Shutterstock

As potentially the first new drug to approach the sickle cell disease market in nearly 20 years and with a limited late-stage pipeline, reception this summer for Emmaus Life Sciences Inc.’s L-glutamine is likely to be strong despite the drug showing only modest benefit in a Phase III trial.

Despite quibbles over the efficacy analysis of the Phase III data, L-glutamine looks set for a US approval following a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Amgen’s MariTide Data Not The Hit Investors Sought

 
• By Joseph Haas

MariTide demonstrated solid 52-week weight loss in a Phase II update, but high rates of vomiting. Amgen is adjusting dosing in Phase III to seek a better tolerability profile.

Positive Fabry Data Should Smooth Way For Sangamo’s Partnering Efforts

 
• By Alaric DeArment

The biotech announced results from the pivotal trial of isaralgagene civoparvovec and plans to file for approval in 2026 as it looks for a commercialization partner.

Industry’s Vaccines Pipeline In A Changing Regulatory Landscape

 
• By Jessica Merrill

More than a dozen vaccines for infectious diseases are in Phase III development across the industry, as the US regulatory environment brings increased uncertainty.